Who is sponsoring NCT05732974?

NCT05732974 is sponsored by University Hospital, Toulouse.

What drugs are being tested in NCT05732974?

Interventions in NCT05732974: Resected non small cell lung cancer.

What condition does NCT05732974 study?

NCT05732974 studies Non-small Cell Lung Cancer Stage IIIA.

Is NCT05732974 still recruiting?

NCT05732974 is currently recruiting now. Last updated 21 September 2023.

Last reviewed 2023-09-21 · How we verify

NCT05732974: MIRACLE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse

Recruiting now Last updated 21 September 2023

What this trial tests

trial testing Resected non small cell lung cancer in Non-small Cell Lung Cancer Stage IIIA in 60 participants. Currently enrolling.

Timeline

30 March 2023

Primary endpoint
30 November 2025

30 October 2026

Quick facts

Lead sponsor	University Hospital, Toulouse
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	60
Start date	30 March 2023
Primary completion	30 November 2025
Estimated completion	30 October 2026
Sites	1 location across France

Drugs / interventions tested

Resected non small cell lung cancer

Conditions studied

Non-small Cell Lung Cancer Stage IIIA — all drugs for Non-small Cell Lung Cancer Stage IIIA →

Sponsor

University Hospital, Toulouse

Who can join

18 and older, any sex, with Non-small Cell Lung Cancer Stage IIIA. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Early-stage non small cell lung cancer represents 20-30% of all non small cell lung cancer and is characterized by a high survival probability after surgical resection. However, considering stage IA-IIIA non small cell lung cancer, a relapse rate of about 50% is observed, with a different survival probability on the basis of tumor node metastasis status, although patients within the same tumor node metastasis stage exhibit wide variations in recurrence rate. There are currently no validated prognostic biomarkers able to identify patients with a high risk of relapse.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

MicroRNAs in lung cancer: their role in tumor progression, biomarkers, diagnostic, prognostic, and therapeutic relevance.
Chatterjee M, Nag S, Gupta S, Mukherjee T, et al · · 2025 · cited 8× · PMID 40067551 · DOI 10.1007/s12672-025-02054-9
Exploring the clinical utility of liquid biopsy with cfDNA in cancer: A systematic review.
Ranganathan K, Kurian NS, Goswami HM, Rishi KD, et al · · 2024 · cited 5× · PMID 40027943 · DOI 10.1016/j.jlb.2024.100150

Verify or expand the search:

Other University Hospital, Toulouse trials

Trials by the same sponsor.

NCT07497750 — Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver D · NA · not yet recruiting
NCT07507240 — The Benefits of a Care Pathway Combining Remote Monitoring and Support From a Nurse After a Change in Anti-epileptic Tre · NA · not yet recruiting
NCT07524088 — Contamination of Young Children Hair During Acute Cannabis Intoxication · NA · not yet recruiting
NCT07470580 — Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension · NA · not yet recruiting
NCT07423988 — Evaluation of Changes in Sleep Efficiency Among PIC DU MIDI Staff Between Nights Spent at Home and Nights Spent in the W · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05732974 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Toulouse
Last refreshed: 21 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05732974.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing